V isceral leishmaniasis (VL) continues to be a major health threat worldwide and is classified as one of the most neglected diseases by the World Health Organization. VL is a chronic infection clinically characterized by progressive fever, weight loss, splenomegaly, hepatomegaly, anemia, and spontaneous bleeding associated with marked inflammatory imbalance (1) . The hallmark of this disease is thought to be a lack of cellular immune responses against the parasite and high systemic levels of IFN-g and IL-10 (2). The New World Leishmania infantum chagasi is the major species implicated in the VL in Brazil. Leishmania parasites are obligate intracellular protozoa that replicate preferentially inside macrophages (3) . It is well known that L. chagasi is able to evade pro-oxidative responses and other macrophage effectors mechanisms (4) , possibly hampering the activation of adaptive immune responses against infection (5) . During parasite-host interactions, complex signaling pathways are triggered by the recognition of key molecules from parasite (4) . In this context, lipophosphoglycan (LPG), a glycoconjugate expressed on the surface of Leishmania parasites and TLR2 agonist (6, 7) , has been implicated in the modulation of a wide range of innate immune functions. Those may include resistance to complement, attachment and entry into macrophages, protection against proteolytic damage within acidic vacuoles (8) , inhibition of phagosomal maturation (9) , modulation of NO and IL-12 production (10) (11) (12) (13) , inhibition of protein kinase C (14) , induction of neutrophil extracellular traps (15) , and induction of protein kinase R (16) . However, specific aspects of how the parasites regulate some protective responses are still unknown. Moreover, it is not fully understood whether LPG from Leishmania is the major regulator of the effectors pathways associated with the protective responses against this protozoan.
Excess of heme is very hazardous for the cells, and we have previously shown that heme suppresses some anti-inflammatory mediators in human malaria caused by Plasmodium vivax (17) . Heme oxygenase-1 (HO-1) is a stress-responsive enzyme that metabolizes heme and releases free iron, carbon monoxide, and biliverdin, which rapidly undergoes conversion to bilirubin (18) . Recently, the HO-1 isoform encoded by the Hmox1 gene has emerged as a key regulator of inflammation by its anti-inflammatory, cytoprotective, antiapoptotic, and antiproliferative effects. Interestingly, HO-1 seems also to modulate innate as well as adaptive immunity (19) . Studies have emphasized the participation of HO-1 in host-tolerance mechanisms facing infections by means of its heme detoxifying activity (20) . Therefore, HO-1 can overcome the pathogenesis of a variety of immune system-mediated inflammatory conditions, such as malaria (20, 21) , ischemia/ reperfusion injury (22) , intrauterine fetal growth restriction (23) , sepsis (24, 25) , graft rejection (26, 27) , and sickle hemoglobin (28) . Intriguingly, the immunomodulatory effects of HO-1 can drive both beneficial and detrimental consequences in the host immunity against infections agents (reviewed in Ref. 29) . In fact, HO-1 protects Plasmodium-infected hepatocytes, thereby promoting the establishment of those parasites (30) . In contrast, HO-1 enhances bacterial clearance during polymicrobial sepsis caused by cecal ligation and puncture (24) , arguing that this antioxidant enzyme plays an important role in the antimicrobial process without inhibiting the inflammatory response (i.e., resistance to infection).
Despite the recognition of the importance of HO-1 in immunoregulatory mechanisms, the direct role of this enzyme in the host cell-Leishmania interplay has not been addressed. Pham and colleagues (31) reported that during infection of macrophages with L. pifanoi, HO-1 is involved in the suppression of superoxide production by inducing heme degradation, which hampers the maturation of gp91 phox , a subunit of NADPH oxidase enzyme complex. However, it was not clear whether this event had any impact in parasite survival or cytokine production.
In the current study, we report that both L. chagasi and LPG isolated from promastigotes induce HO-1 expression in murine macrophages. Interestingly, stimulation of macrophages with cobalt protophorphyrin IX (CoPP), a pharmacologic inductor of HO-1, resulted in a significant increase of the parasite burden. Upon L. chagasi infection, bone marrow-derived macrophages (BMMs) from Hmox1 2/2 mice showed lower parasite loads then macrophages from wild-type (WT) mice. Finally, we found that HO-1 is strongly associated with human VL in a cohort of patients from a highly endemic area in Brazil. These results represent the first evidence, to our knowledge, for the importance of HO-1 in regulating host immune responses to L. chagasi infection. Our study opens up new perspectives suggesting that HO-1 might be a therapeutic target for human VL.
Materials and Methods

Reagents
CoPP (Frontier Scientific, Logan, UT) was dissolved in 0. Mouse and human macrophages C57BL/6 mice were injected i.p. with 3% thioglycolate solution. Four days after injection, peritoneal lavage was performed using 8 ml RPMI 1640 medium supplemented with 1% Nutridoma-SP, 2 mM L-glutamine, 100 U/ ml penicillin, and 100 mg/ml streptomycin. BMMs from Hmox1 2/2 and Hmox1 +/+ mice from both BALB/c and SCID strains were cultured in RPMI 1640 medium containing 20% FBS, gentamicin, HEPES, and 20% L929-conditioned medium for 7 d. Human monocytes were isolated from peripheral blood of healthy donors through Ficoll gradient centrifugation and plastic adherence; cells were cultivated in RPMI 1640 medium supplemented with 10% FBS for 7 d to obtain differentiated macrophages in vitro. In some experiments, total PBMCs from normal blood donors were infected with L. chagasi in the presence of 1 mM PTX, an inhibitor of TNF-a production, for 12 h.
Infection assays
Macrophages (3 3 10 5 ) were seeded onto glass coverslips in 24-well plates. Cells were allowed to adhere for 2 h at 37˚C and 5% CO 2 ; nonadherent cells were removed by washing each well with sterile saline. L. chagasi promastigotes in early stationary phase were added to macrophage cultures at a macrophage/parasite ratio of 1:10 in RPMI 1640 medium supplemented with 10% inactive FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. Macrophages (1 3 10 6 ) were seeded on 48-well plates in the experiments in which the cell lysate or supernatants were used for HO-1 or cytokine measurements. The pharmacological modulation of HO-1 during the L. chagasi infection was performed in presence of CoPP, an inductor of HO-1 production (32). After 4 h, infected cells were washed to remove extracellular parasites, fresh medium was replaced with the same stimuli, and plates were returned to the incubator until the desired time. After 4, 24, 48, and 72 h, supernatants were harvested and cleared by centrifugation and stored at 220˚C. Cells on glass coverslips were fixed with methanol and stained by Diff-Quick (American Scientific Products, McGraw Park, IL). Intracellular amastigotes were counted under light microscopy in 200 macrophages per slide in a blind fashion manner. Results are shown as amastigote number per 100 macrophages and percentage of infected macrophages in relation to control (group infected only with L. chagasi). Alternatively, intracellular load of L. chagasi was estimated by production of viable promastigotes in Schneider medium as described previously (33) . Briefly, after 72 h of infection, RPMI 1640 medium was replaced by Schneider medium supplemented with 20% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin, and the plate was then kept at 24˚C. Intracellular survival of L. chagasi was quantified by counting proliferating extracellular motile promastigotes in a Neubauer hemocytometer until the seventh day after the medium replacement. To rule out a possible toxicity induced in cells or parasites treated with porphyrins, we performed a cell viability assay using XTT (Roche Applied Science). In some experiments, macrophages were incubated with LPS (100 ng/ml) or pretreated overnight with an antagonist (5 mM GW9662) or an agonist (10 mM rosiglitazone) of the peroxisome proliferator-activated receptor g (PPARg).
HO-1 measurement by ELISA
Murine and human macrophages were infected with L. chagasi or treated with LPG and HO-1 was measured in supernatants or cell lysates obtained through the use of lysis buffer available in murine and human HO-1 ELISA kit, following the manufacturer's instructions.
Measurements of the inflammatory mediators
TNF-a, IL-6, MCP-1, and IL-10 were measured in cell supernatants using a cytometric bead array mouse inflammation kit. NO production was measured in the supernatants of L. chagasi-infected macrophages pretreated with 100U/ml IFN-g by the Griess method, as described elsewhere (34, 35) . Intracellular reactive oxygen species (ROS) levels were measured by staining with the oxidative fluorescent dye probe DHE 5 mM (Invitrogen/Molecular Probes, Grand Island-NY) for 30 min at 37˚C and then analyzed using flow cytometer (FACSCalibur; BD Biosciences, San Jose, CA) using the FL2 emission filter. Data were displayed as histograms, and the geometric median fluorescence intensity was evaluated using FlowJo software (Tree Star, Ashland, OR).
HO-1 measurements in VL serum samples
Serum samples were obtained from patients with VL (n = 52) and sexmatched endemic healthy controls (HC) (n = 42) from an endemic area in the Northeast of Brazil. The baseline characteristics of the study participants are shown in the Supplemental Table I . The patients with VL were followed up and HO-1 was measured before the antileishmanial therapy and after the treatment was finished due to clinical cure. HO-1 was measured using a human ELISA kit following the manufacturer's instructions. This study was approved by Institutional Review Board of Federal University of Sergipe, Brazil, where the field study was performed. All clinical investigations were conduced according to the Declaration of Helsinki. Written informed consent was obtained from all participants or legal guardians.
Statistical analysis
Each experiment was performed at least three times, and at least five mice were used in each experimental group. Data are reported as mean 6 SD of representative experiments and were analyzed using GraphPad Prism Software 5.0 (GraphPad, San Diego, CA). After performing a normality test, Kruskal-Wallis nonparametric test followed by Dunn's posttest or linear trend analysis were used to evaluate statistical significance among the groups. In some assays, comparisons between two groups were explored using the Mann-Whitney U test. Correlations among HO-1 and IL-10, TNF-a, and IL-6 were performed using the Spearman test. The Wilcoxon matched pairs test was performed to estimate statistical significance before and after the antileishmanial treatment. Receiver-operator characteristic (ROC) curves with C-statistics were used to establish the threshold value of HO-1 able to discriminate between VL and HC. A logistic regression model adjusted for age was also applied to check the strength of the association between HO-1 systemic concentrations and the occurrence of VL. A p value ,0.05 was considered statistically significant.
Results
L. chagasi infection enhances HO-1 expression by mouse macrophages
Crescent concentrations of HO-1 protein were detected in mouse peritoneal macrophages infected with L. chagasi compared with uninfected cells (Fig. 1A, 1B) , with significant trend to increase over time postinfection (linear trend p , 0.0001) in either cellculture supernatants (Fig. 1A ) or cell lysates (Fig. 1B) . In addition, infected macrophages treated with 50 mM CoPP, an inductor of HO-1 (32), amplified the production of HO-1 (Fig. 1C, 1D ), when compared with L. chagasi-infected macrophage alone. Because HO-1 is a microsomal enzyme, and we were able to detect HO-1 protein in the culture supernatants, cell death could be occurring during in vitro infection. To rule out an important toxic effect of CoPP in cell culture, we tested whether treatment with this porphyrin could affect cell viability. The stimulus was not significantly toxic for either infected macrophages (Supplemental Fig.  1A ) or Leishmania parasites (Supplemental Fig. 1B ). As expected, HO-2, the constitutive form of HO, remained unchanged in both infected macrophages or with CoPP treatment (data not shown). Therefore, we conclude that mouse macrophages display consistently high amounts of HO-1 upon infection with L. chagasi.
HO-1 promotes L. chagasi infection in macrophages
Once inside macrophages, Leishmania parasites may circumvent various host defense mechanisms to survive. Because HO-1 induction is associated with the persistence of Plasmodium in the liver (30) and also favors Mycobacterium tuberculosis inside macrophages during a latent infection via induction of the dormancyassociated genes (36), we hypothesized that the elevated concentrations of HO-1 detected in infected macrophages treated with CoPP could bring key benefits for the Leishmania. To address this question, we infected murine macrophages in vitro in presence of CoPP and evaluated the parasite load. Our experiments revealed that induction of HO-1 led to an increased in the percentage of infected macrophages ( Fig. 2A) , number of intracellular amastigotes (Fig. 2B) , and viability of L. chagasi inside macrophages (Fig. 2C) , whereas inhibition of HO-1 activity by Tin protoporphyrin had no impact on the parasite burden (data not shown). Interestingly, BMMs from Hmox1 2/2 mice from either BALB/c (Fig. 2D) or SCID (Fig. 2E ) mouse strains presented significantly reduced parasite burden compared with the strain-matched WT. Infected BMMs from Hmox1 2/2 mice from both genetic backgrounds incubated or not with CoPP displayed reduced Leishmania viability at different time points postinfection, confirming that the primary effect of CoPP on parasite survival within macrophages was due to the induction of HO-1 (Fig. 2D, 2E ). These results are consistent with the idea that induction of HO-1 by infected macrophages is a key event promoting Leishmania survival.
HO-1 regulates the production of proinflammatory mediators by L. chagasi-infected macrophages
It is well established that the essential mechanisms of protection against Leishmania involves activation of macrophages and production of proinflammatory cytokines, ROS (37, 38) , and NO (39) . In this study, we addressed whether the role of HO-1 in promoting Leishmania persistence within macrophages involves regulation of proinflammatory cytokines and/or oxidative stress. Induction of HO-1 by CoPP decreased production of TNF-a (Fig. 3A) , but did produced higher amounts of TNF-a than WT cells upon infection (Fig. 3C) , reinforcing the participation of HO-1 in the modulation of TNF-a production. Moreover, macrophages primed with IFN-g presented significantly diminished NO production when treated with CoPP (Fig. 3D ). Additionally, we tested if the modulation of the proinflammatory mediators induced by HO-1 could be robust enough to revert the inflammatory profile of infected macrophages primed with LPS. Indeed, induction of HO-1 by CoPP consistently increased parasite burden (Supplemental Fig. 2A ) and reduced production of TNF-a (Supplemental Fig. 2B ), NO (Supplemental Fig. 2E ), IL-6 (Supplemental Fig. 2F ), and MCP-1 (Supplemental Fig. 2G ), but not IL-10 (Supplemental Fig. 2C ) by these cells. Thus, a higher IL-10/TNF-a ratio was found in infected macrophages primed with LPS upon induction of HO-1 (Supplemental Fig. 2D ). In addition, CoPP treatment reduced L. chagasi-induced ROS production by macrophages (Fig. 3E, 3F ). These data suggest that HO-1 promotes Leishmania survival within macrophages by precluding inflammation and oxidative stress.
L. chagasi promastigotes and LPG induce HO-1 independently of PPARg activation
LPG from the cell surface of Leishmania promastigotes has been described as a major virulence factor (40), involved in the ability to induce lesions in mice (41) and activation of immune cells (15) . To test if this virulence factor from the parasite surface could be able to induce HO-1, we incubated macrophages with LPG isolated from the L. chagasi strain Ba262. Indeed, LPG was capable of inducing HO-1 production by mouse macrophages (Fig. 4B) . HO-1 expression is transcriptionally regulated by PPARg (42) . Because PPARg is induced by L. donovani and could exacerbate the disease in a chronic experimental model of VL (43), we determined whether PPARg was involved in the induction of HO-1 by L. chagasi and its LPG. Interestingly, induction of HO-1 by macrophages stimulated with L. chagasi (Fig. 4A) or LPG (Fig.  4B ) persisted in the presence of a PPARg antagonist (GW 9662) or an agonist (rosiglitazone). Thus, the induction of HO-1 does not seem to be regulated by PPARg in the context of L. chagasi infection.
HO-1 promotes Leishmania persistence in human macrophages
To verify if our results were reproducible in human macrophages, we performed in vitro infections with L. chagasi in the presence of CoPP. Induction of HO-1 favored increased percentage of infected macrophages (Fig. 5A) , number of intracellular amastigotes (Fig.  5B) , and the viability of L. chagasi inside macrophages (Fig. 5C ).
With an attempt to verify a potential mechanism by which the induction of HO-1 favors L. chagasi persistence inside the human macrophages, we tested surrogates of the oxidative stress. Treatment of the cells with CoPP led to reduction in the production of superoxide radicals triggered by L. chagasi infection (Fig. 5D) . Interestingly, some antioxidant mechanisms of HO-1 require interplay with another class of antioxidant enzyme, the superoxide dismutase (44, 45) . Therefore, we investigated the association between the induction of HO-1 and SOD-1. Notably, SOD-1 has been shown to favor Leishmania growth in human macrophages (35) . We found hereby that the induction of HO-1 by CoPP upon L. chagasi infection is also associated with induction of SOD-1 protein (Fig. 5E ) in human macrophages. These findings argue that induction of HO-1 favors Leishmania survival by its antioxidant activities per se and also by the induction of superoxide dismutases, which are potent scavengers of superoxide anions generated during infection.
HO-1 is strongly associated with human visceral leishmaniasis
The ultimate goal of our current investigation was to investigate whether HO-1 was associated with the human disease caused by L. chagasi infection. We then evaluated serum samples obtained from patients with VL and sex-matched endemic controls from a highly endemic area in the northeast of Brazil. The baseline characteristics of the study participants are shown in Supplemental Fig. 6B ). An analysis using ROC curves revealed that HO-1 could be used to discriminate patients with VL from those uninfected in the cohort studied (Fig. 6C ). In individuals with VL, HO-1 presented positive correlation with IL-10 (r = 0.56; p , 0.0001; Fig. 6F ), a major factor involved in the clinical severity of VL (46, 47) . HO-1 was also correlated with diverse markers of systemic inflammation, such as TNF-a (r = 0.23; p = 0.0117; Fig. 6D ), IL-6 (r = 0.58; p , 0.0001; Fig. 6G ), and IL-8 (r = 0.44; p , 0.0001; Fig. 6H ). These results reinforce the notion that HO-1 is associated with L. chagasi in humans and that HO-1 may be linked to susceptibility to human VL. Given that HO-1 is a stress-responsive gene, this finding is consistent with the notion that the disease is associated with increased oxidative stress, thereby explaining the increased level of expression of this enzyme. As expected, after the antileishmanial treatment, systemic levels of TNF-a were reduced (p , 0.001; Fig. 6E ) and no longer correlated with HO-1 (r = 0.4920; p = 0.0625). The next step was to test whether it is possible to interfere with HO-1 expression by inhibiting proinflammatory cytokines in human cells. We found that treatment of human PBMC with PTX, a pharmacological TNF-a inhibitor with wide clinical use, resulted in reduction of HO-1 production upon infection with L. chagasi (Supplemental Fig. 3A, 3B ).
Discussion
Studies have emphasized that the cytoprotective enzyme HO-1 plays a pivotal role in maintaining cellular homeostasis during inflammation (48) , and its expression is increased in a variety of pathological conditions (29) . The protective actions of HO-1 during infection are usually associated with the reduction in immunopathology caused by the oxidative stress (49, 50) . Indeed, a higher expression of HO-1 results in diminished damage of cells and tissues even at the relatively high infection burden, what is called tolerance to infection (20, 51) . In this study, we show that HO-1 seems to affect host effector molecules that drive resistance to infection, such as inflammatory cytokines and free radicals, which favors Leishmania persistence. Our results also suggest that HO-1 may play an essential dual role during Leishmania infection. On one hand, HO-1 can protect host tissues against injury by damping excess of inflammation. On the other hand, induction of HO-1 protects the parasite against the host defense. Similarly, upon Plasmodium infection, induction of HO-1 seems to be an The Journal of Immunologyobligatory step in the liver stage by controlling host innate inflammatory responses and protecting infected hepatocytes from cell death (21, 30) . To date, little is known about the role of HO-1 in L. chagasi pathogen burden, and our data demonstrate that HO-1 enhances L. chagasi survival within host macrophages and that HO-1 is a highly associated with human VL. We propose that HO-1 plays two major roles following L. chagasi infection: 1) prevents damage to host cells; and 2) decreases the host ability to limit the intracellular growth of the parasite. Hmox1 gene expression involves multiple pathways, including redox-dependent and -independent signaling molecules and immune mediators (52) (53) (54) . Most of the studies that tried to address the role of HO-1 in infectious diseases have been focused on the anti-inflammatory effects, especially during malaria infection. Indeed, Pamplona and colleagues (20) have demonstrated that infection of BALB/c mice with Plasmodium berghei causes upregulation of HO-1 in the brain. It has been also suggested that P. berghei infection upregulates HO-1 in hepatocytes in vivo and peritoneal macrophages in vitro (30) . In the current study, we observed that L. chagasi infection induced HO-1 in mouse macrophages, whereas concentrations of HO-2, the constitutive HO isoform, remained unchanged upon infection or treatment with CoPP. The obvious further step was to try to identify what molecule from the parasite would be able to trigger HO-1. A natural candidate would be LPG, which is the major Leishmania parasite surface molecule and has been implicated in Leishmania survival within mammalian macrophages in vitro (41, 55) . Interestingly, we found that LPG was able to strongly induce HO-1 in mouse macrophages. Although tempted, we cannot assume that LPG is the most important trigger for HO-1 induction, because we did not rule out other Leishmania surface proteins. The absence of available mutants for L. chagasi still underlines the need for further experiments. After the identification of a possible trigger, we tested whether PPARg, a known transcription factor of upstream Hmox1 gene activation (42) , would be involved in L. chagasi-induced HO-1 expression. PPARg has been implicated in alternative activation of macrophages upon infection with L. major, which favors parasite survival (56) and interferes with adaptive immunity to exacerbate the pathogenesis of experimental VL (43) . Our experiments performed using macrophages cocultured with an agonist or an antagonist of PPARg showed no alteration in HO-1 induction by either L. chagasi or LPG, suggesting that PPARg does not seem to be the major orchestrator of Hmox1 induction in this experimental model. Thus, the specific transcription factors upstream of HO-1 that are induced by Leishmania or LPG remain to be determined.
Our results suggest that the HO-1 expression in macrophages is an important subversion mechanism by which Leishmania parasites can escape from the oxidative burst. Similarly, Pham and colleagues (31) have shown that L. pifanoi avoids elicitation of superoxide production during their internalization, and this phenomenon is dependent on HO-1 production. However, the authors did not address whether this escape via HO-1 has any impact on infection burden and Leishmania survival. Our study expands the current knowledge, as we demonstrate that induction by HO-1 by CoPP markedly increases parasite burden within infected macrophages. We then tested whether the genetic deficiency of HO-1 expression would be associated with modulation of parasite burden. Indeed, we found that lack of HO-1 expression leads to a significant reduction in parasite load and that this effect was correlated with a higher TNF-a production in response to infection, indicating that expression of Hmox1 gene promotes Leishmania survival. In fact, infection burdens in BMMs from Hmox1 2/2 mice treated with CoPP were unaffected, indicating that CoPP acts through HO-1 to favor parasite persistence. We propose that in L. chagasi infection, HO-1 plays a similar role as in malaria, in which overexpression of HO-1 increases P. berghei liver infection, and that HO-1 is required to protection of infected hepatocytes by controlling the inflammatory responses (30) . TNF-a is a central inflammatory cytokine in the induction of macrophage antimicrobial activities (57, 58) and has been associated with disease severity in patients with VL (59, 60) . In fact, we found that induction of HO-1 reduced production of TNF-a and ROS upon L. chagasi infection of macrophages, consistent with mechanisms of cell protection by HO-1 (48) . Furthermore, induction of HO-1 caused reduction of proinflammatory mediators such as NO, MCP-1, and IL-6 by macrophages primed with IFN-g or LPS. A recent study suggested that LPS might contribute to the cytokine storm and cellular activation in patients with VL (61) . We propose that HO-1 is probably increasing the tolerance to L. chagasi infection by reducing the inflammatory status of activated macrophages and that this is probably critical in human VL, which is frequently associated with bacterial coinfection.
Finally, our findings on human macrophages confirm that HO-1 induction increases parasite load and indicate that this mechanism may be important for the pathogenesis of human disease. Patients with VL had higher serum levels of HO-1 than those not infected, and the systemic concentrations of HO-1 were significantly reduced at 15 d post-antileishmanial treatment. HO-1 is primarily thought to be an intracellular enzyme (62) , and the increased serum levels of HO-1 suggest that some degree of cell death is occurring during VL. Indeed, knowing the source of extracellular HO-1 is still needed. Our data show that high concentrations of serum HO-1 are associated with a higher chance to have VL in our cohort of patients. Consistent with our results, increased concentrations of HO-1 have already been associated with other diseases such as vasculitis in Henoch-Schonlein purpura (63), hemophagocytic syndromes from hematological conditions (64, 65) , type 2 diabetes (66) , and prostate cancer (67) . Thus, although showing strong associations between HO-1 and VL, our study expands the list of the diseases in which HO-1 potentially plays a fundamental role. In the current study, we also show that systemic concentrations of HO-1 are positively correlated to diverse cytokines, such as TNF-a, IL-6, IL-8, and IL-10. In this context, HO-1 could play a role similar to the one previously described for IL-10, which is anti-inflammatory but strongly associated with inflammatory conditions and also in human VL (2, 46) . We found positive correlation between serum HO-1 and TNF-a. Of note, there is increased production of several cytokines and chemokines in VL patients, and much of the response appears to be proinflammatory, as indicated by the elevated plasma protein levels of IL-1, IL-6, IL-8, and TNF-a (reviewed in Ref. 58 ). Indeed, elevated serum levels of TNF-a have been associated with VL (60) . We speculate that the systemic amounts of the proinflammatory cytokines could be even higher in the absence of HO-1. The high levels of TNF-a and cytokine storm, features of VL, could be inducing higher levels of HO-1 as a counterregulatory response. Similar to our results, patients with hemophagocytic syndrome also present a positive correlation between HO-1 expression and serum TNF-a (65), suggesting that this pattern may be common in inflammatory conditions in vivo. Our results argue that it is possible that the susceptibility to infection would be worse in case of the lack or absence of HO-1 in human VL. Whether the systemic concentrations of the cytokines and HO-1 evaluated in this study represent their respective amounts in the tissues in which the infected cells are localized deserves further investigation.
In summary, the current study shows that HO-1 drives L. chagasi infection within macrophages by means of its anti-inflammatory properties, reinforcing that Hmox1 gene is required for Leishmania survival and persistence. Moreover, we show that HO-1 is strongly associated with human VL. Therefore, HO-1 may represent an important escape mechanism required for the control of Leishmania replication by immune cells and could be used as a therapeutic target to reduce VL severity. Protection against excessive inflammatory response may preclude deleterious effects of VL. 
